secwatch.observer — SEC 8-K summary
======================================

Issuer:     GT Biopharma, Inc. (GTBP)
CIK:        0000109657
Form:       8-K
Filed at:   2024-06-07T23:59:59+00:00
Accession:  0001493152-24-023195
Event type: leadership
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

GT Biopharma appoints Alan Urban as CFO after terminating Manu Ohri
-------------------------------------------------------------------

- Manu Ohri's employment as CFO terminated effective June 3, 2024.
- Alan L. Urban appointed CFO; previously CFO at SRAX, Creek Road Miners, Research Solutions.
- Urban receives $375,000 base salary, up to 40% bonus, and equity award eligibility after 3 months.
- Employment agreement for one-year initial term with automatic renewal and severance terms.
- Urban reports to Executive Chairman & Interim CEO Michael Breen.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/109657/000149315224023195/0001493152-24-023195-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/109657/000149315224023195/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-023195

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer